PET Scan Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9
Tests a PET scan tracer in adults with leukemia, melanoma, or lung cancer.
Key facts
- Who runs it
- Turku University Hospital
- Where
- Turku, FinlandSee the site
- Trial code
- Registry title
- PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9
- Status
- Enrolling by invitation
- People taking part
- 30 people, planned
- Started
- 1 Sept 2023
- Expected to end
- 31 Dec 2026
- Type of study
- Observational
- Record updated
- 4 December 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with acute myeloid leukemia, metastatic melanoma or metastatic non-small cell lung cancer who are about to start cancer treatment. It uses a PET/CT scan.
- Age
- 18 Years to 100 Years
- Sex
- All sexes can join.
- Disease stage
- Acute myeloid leukemia (AML) fit for allogeneic stem cell transplantation; metastatic melanoma fit for immune checkpoint inhibitors or BRAF- and MEK inhibitors; metastatic non-small cell lung cancer (NSCLC), stage IV, fit for immune checkpoint inhibitors and/or chemotherapy.
Main reasons for not taking part
- People who cannot have the planned cancer treatment cannot join.
- People unable or unwilling to follow the study protocol cannot join.
- People with serious uncontrolled other diseases (nerve, kidney, liver, hormone or gut) that the investigator thinks prevent taking part cannot join.
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Diagnosis of acute myeloid leukemia (AML) and fit for allogeneic hematopoietic stem cell transplantation (alloHSCT), as assessed in the standard operating procedures
- Diagnosis of metastatic melanoma and fit for immune checkpoint inhibitors or BRAF- and MEK inhibitors
- Diagnosis of metastatic non-small cell lung cancer (NSCLC) (stage IV) and fit for immune checkpoint inhibitors and/or chemotherapy
- Able and willing to give written informed consent and to comply with the study protocol
Who cannot take part
- Unsuitable for alloHSCT (AML), checkpoint inhibitors or BRAF- and MEK inhibitors (melanoma or checkpoint inhibitors and/or chemotherapy (NSCLC) according to the standard operating procedures
- Evidence of significant uncontrolled concomitant diseases such as neurological, renal, hepatic, endocrine, or gastrointestinal disorders which, in the opinion of the Investigator, would preclude patient participation
- Unable or unwilling to comply with the study protocol for any reason
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Where in Finland
- Turku University Hospital, Turku PET CentreTurku, FinlandNo longer taking part
About the trial
What the trial wants to find out
This is a scientific study to determine expression of vascular adhesion protein 1 (VAP-1) in cancer patients by 68Ga-DOTA-Siglec-9 positron emission tomography/computed tomography (PET/CT) before and after cancer treatment.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9
- Plain-language title
- PET Scan Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9Generated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05212103, who can take part
- Publications
- Record updated
- 4 December 2024